{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:15:49Z","timestamp":1791404149440,"version":"4.3.3"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40259-022-00533-x","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T06:28:04Z","timestamp":1653114484000},"page":"359-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-0305","authenticated-orcid":false,"given":"Pekka","family":"Kurki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Na","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Ekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Wolff-Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"533_CR1","unstructured":"WHO Expert Committee on Biological Standardization.2013. Annex 2. Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Technical Report Series no. 977. http:\/\/who.int\/biologicals\/publications\/trs\/areas\/biological_therapeutics\/TRS_977_Annex_2.pdf Accessed 12 Nov 2021."},{"key":"533_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biologicals.2020.02.005","volume":"65","author":"HN Kang","year":"2020","unstructured":"Kang HN, Thorpe R, Knezevic I, Survey participants from 19 countries. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals. 2020;65:1\u20139. https:\/\/doi.org\/10.1016\/j.biologicals.2020.02.005.","journal-title":"Biologicals"},{"key":"533_CR3","unstructured":"World Health Organization Expert Committee on Biological Standardization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). In: sixty-seventh report, WHO technical report series 1004, 93\u2013127. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255657\/1\/9789241210133-eng.pdf. Accessed 12 Nov 2021."},{"key":"533_CR4","unstructured":"World Health Organization. Questions and Answers: similar biotherapeutic products. 2018. https:\/\/www.who.int\/biologicals\/expert_committee\/QA_for_SBPs_ECBS_2018.pdf?ua=. Accessed 12 Nov 2021."},{"key":"533_CR5","unstructured":"WHO Expert Committee on Biological Standardization: Report of the seventy-second and seventy-third meetings. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1030; https:\/\/www.who.int\/publications\/i\/item\/9789240024373) Accessed 13 May 2022."},{"key":"533_CR6","unstructured":"FDA. Biosimilars guidelines. https:\/\/www.fda.gov\/vaccines-blood-biologics\/general-biologics-guidances\/biosimilars-guidances. Accessed 7 Dec 2021."},{"key":"533_CR7","unstructured":"Health Canada. Information and Submission Requirements for Biosimilar Biologic Drugs. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/migration\/hc-sc\/dhp-mps\/alt_formats\/pdf\/brgtherap\/applic-demande\/guides\/seb-pbu\/seb-pbu-2016-eng.pdf Accessed 8 Dec 2021."},{"key":"533_CR8","unstructured":"EMA: Multidisciplinary scientific guidelines: biosimilars. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/scientific-guidelines\/multidisciplinary\/multidisciplinary-biosimilar. Accessed 7 Dec 2021"},{"key":"533_CR9","unstructured":"FDA. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. https:\/\/www.fda.gov\/media\/88622\/download. Accessed 23 Feb 2021."},{"key":"533_CR10","unstructured":"FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. https:\/\/www.fda.gov\/media\/82647\/download. Accessed 15 July 2021"},{"issue":"1","key":"533_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/nyas.14522","volume":"1491","author":"HN Kang","year":"2021","unstructured":"Kang HN, Thorpe R, Knezevic I, Casas Levano M, Chilufya MB, Chirachanakul P, et al. Regulatory challenges with biosimilars: an update from 20 countries. Ann N Y Acad Sci. 2021;1491(1):42\u201359.","journal-title":"Ann N Y Acad Sci"},{"key":"533_CR12","unstructured":"FDA. Questions and Answers on Biosimilar Development and the BPCI Act. Guidance for Industry. Rev 2, 2021. https:\/\/www.fda.gov\/media\/119258\/download. Accessed 7 Dec 2021."},{"key":"533_CR13","unstructured":"EMA. Guideline on similar biological medicinal products. Revision 1 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 8 Dec 2021."},{"issue":"4","key":"533_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40259-017-0227-4","volume":"31","author":"CJ Webster","year":"2017","unstructured":"Webster CJ, Woollett GR. A \u2018global reference\u2019 comparator for biosimilar development. BioDrugs. 2017;31(4):279\u201386. https:\/\/doi.org\/10.1007\/s40259-017-0227-4.","journal-title":"BioDrugs"},{"issue":"4","key":"533_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40259-019-00357-2","volume":"33","author":"CL Tu","year":"2019","unstructured":"Tu CL, Wang YL, Hu TM, Hsu LF. Analysis of pharmacokinetic and pharmacodynamic parameters in EU-versus US-licensed reference biological products: are in vivo bridging studies justified for biosimilar development? BioDrugs. 2019;33(4):437\u201346. https:\/\/doi.org\/10.1007\/s40259-019-00357-2.","journal-title":"BioDrugs"},{"key":"533_CR16","unstructured":"EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf. Accessed 8 Dec 2021"},{"key":"533_CR17","unstructured":"EMA. Committee for Medicinal Products for Human Use (CHMP) Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf. Accessed 7 Dec 2021."},{"key":"533_CR18","unstructured":"FDA. Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations. Draft guidance https:\/\/www.federalregister.gov\/documents\/2019\/05\/22\/2019-10667\/development-of-therapeutic-protein-biosimilars. Accessed 10 Nov 2021."},{"key":"533_CR19","unstructured":"EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Revision 1 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 8 Dec 2021."},{"key":"533_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104415","volume":"107","author":"P Pipalava","year":"2019","unstructured":"Pipalava P, Patel R, Mehta M, Dahiya M, Singh I, Jose V. An update on the animal studies conducted for biosimilar approvals\u2014regulatory requirement vs actual scenario. Regul Toxicol Pharmacol. 2019;107: 104415. https:\/\/doi.org\/10.1016\/j.yrtph.2019.104415 (Epub 2019 Jun 26 PMID: 31254556).","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"533_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/19420862.2016.1145331","volume":"8","author":"K Chapman","year":"2016","unstructured":"Chapman K, Adjei A, Baldrick P, et al. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. MAbs. 2016;8(3):427\u201335. https:\/\/doi.org\/10.1080\/19420862.2016.1145331 (PMID: 26854177; PMCID: PMC4966840).","journal-title":"MAbs"},{"issue":"5","key":"533_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.4161\/mabs.29848","volume":"6","author":"L van Aerts","year":"2014","unstructured":"van Aerts L, De Smet K, Gabriele R, van der Laan JW, Schneider CK. Biosimilars entering the clinic without animal studies. MAbs. 2014;6(5):1155\u201362. https:\/\/doi.org\/10.4161\/mabs.29848.","journal-title":"MAbs"},{"key":"533_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.drudis.2014.11.009","volume":"20","author":"PJK van Meer","year":"2015","unstructured":"van Meer PJK, Ebbers H, Kooijman M, et al. Contribution of animal studies to evaluate the similarity of biosimilars to reference product. Drug Discov Today. 2015;20:483\u201390.","journal-title":"Drug Discov Today"},{"key":"533_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40259-019-00371-4","volume":"33","author":"CJ Webster","year":"2019","unstructured":"Webster CJ, Wong AC, Woollett GR. An Efficient development paradigm for biosimilars. BioDrugs. 2019;33:603\u201311. https:\/\/doi.org\/10.1007\/s40259-019-00371-4.","journal-title":"BioDrugs"},{"issue":"6","key":"533_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","volume":"33","author":"E Wolff-Holz","year":"2019","unstructured":"Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621\u201334. https:\/\/doi.org\/10.1007\/s40259-019-00377-y.","journal-title":"BioDrugs"},{"key":"533_CR26","unstructured":"EMA. Guideline on Immunogenicity assessment of therapeutic proteins. Rev 1 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revis12.11.ion-1_en.pdf. Accessed 12 Nov 2021"},{"key":"533_CR27","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-021-01601-21","volume":"81","author":"P Kurki","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, Tsintili P, Wolff-Holz E. Safety, Immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881\u201396. https:\/\/doi.org\/10.1007\/s40265-021-01601-21.","journal-title":"Drugs"},{"key":"533_CR28","unstructured":"EMA. Biosimilars https:\/\/www.ema.europa.eu\/en\/medicines\/search_api_aggregation_ema_medicine_types\/field_ema_med_biosimilar\/ema_group_types\/ema_withdrawn_applications\/ema_group_types\/ema_medicine. Accessed 9 Dec 2021."},{"key":"533_CR29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.phrs.2017.10.015","volume":"128","author":"C Blandizzi","year":"2018","unstructured":"Blandizzi C, Galeazzi M, Valesini G. Transitioning from first- to second-generation biosimilars: an appraisal of regulatory and post-marketing challenges. Pharmacol Res. 2018;128:306\u201314.","journal-title":"Pharmacol Res"},{"issue":"3","key":"533_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000508190","volume":"93","author":"R Pf\u00e4ffle","year":"2020","unstructured":"Pf\u00e4ffle R, Bidlingmaier M, Kreitschmann-Andermahr I, et al. Safety and effectiveness of Omnitrope\u00ae, a biosimilar recombinant human growth hormone: more than 10 years\u2019 experience from the PATRO Children Study. Horm Res Paediatr. 2020;93(3):154\u201363. https:\/\/doi.org\/10.1159\/000508190 (Epub 2020 Aug 19 PMID: 32814319).","journal-title":"Horm Res Paediatr"},{"key":"533_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12902-019-0464-2","volume":"19","author":"P Beck-Peccoz","year":"2019","unstructured":"Beck-Peccoz P, H\u00f6ybye C, Murray RD, et al. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope\u00ae): data from an observational, longitudinal study. BMC Endocr Disord. 2019;19:138. https:\/\/doi.org\/10.1186\/s12902-019-0464-2.","journal-title":"BMC Endocr Disord"},{"key":"533_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2147\/DDDT.S130320.PMID:28553079;PMCID:PMC5439972","volume":"11","author":"JP L\u00f3pez-Siguero","year":"2017","unstructured":"L\u00f3pez-Siguero JP, Pf\u00e4ffle R, Chanson P, Szalecki M, H\u00f6bel N, Zabransky M. Ten years\u2019 clinical experience with biosimilar human growth hormone: a review of efficacy data. Drug Des Dev Ther. 2017;11:1489\u201395. https:\/\/doi.org\/10.2147\/DDDT.S130320.PMID:28553079;PMCID:PMC5439972.","journal-title":"Drug Des Dev Ther"},{"key":"533_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2042018820943377","volume":"11","author":"P Beck-Peccoz","year":"2020","unstructured":"Beck-Peccoz P, H\u00f6ybye C, Murray RD, et al. Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope\u00ae): data from the PATRO Adults study. Ther Adv Endocrinol Metab. 2020;11:1\u201312. https:\/\/doi.org\/10.1177\/2042018820943377 (PMID: 32973992; PMCID: PMC7491215).","journal-title":"Ther Adv Endocrinol Metab"},{"key":"533_CR34","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00520-018-4522-5","volume":"27","author":"CN Abboud","year":"2019","unstructured":"Abboud CN, Lang N, Fung H, et al. Real-world safety experience of tevagrastim\/ratiograstim\/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. Support Care Cancer. 2019;27:2569\u201377. https:\/\/doi.org\/10.1007\/s00520-018-4522-5.","journal-title":"Support Care Cancer"},{"key":"533_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jgo.2016.09.006","volume":"8","author":"M Aapro","year":"2017","unstructured":"Aapro M, Bokemeyer C, Ludwig H, et al. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: patterns, outcomes, and determinants (MONITOR-GCSF study). J Geriatr Oncol. 2017;8:86\u201395.","journal-title":"J Geriatr Oncol"},{"key":"533_CR36","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1111\/trf.13853","volume":"56","author":"P Becker","year":"2016","unstructured":"Becker P, Schwebig A, Brauninger S, et al. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: Safety, efficacy, and graft performance. Transfusion. 2016;56:3055\u201364.","journal-title":"Transfusion"},{"key":"533_CR37","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1002\/cam4.3261","volume":"9","author":"K-W Kang","year":"2020","unstructured":"Kang K-W, Lee B-H, Jeon MJ, et al. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim. Cancer Med. 2020;9:6102\u201310.","journal-title":"Cancer Med"},{"issue":"6","key":"533_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41409-018-0350-y","volume":"54","author":"S Pahnke","year":"2019","unstructured":"Pahnke S, Egeland T, Halter J, et al. Working Group Medical of the World Marrow Donor Association. Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant. 2019;54(6):858\u201366. https:\/\/doi.org\/10.1038\/s41409-018-0350-y.","journal-title":"Bone Marrow Transplant"},{"key":"533_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469\u201375.","journal-title":"N Engl J Med"},{"issue":"1","key":"533_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5414\/cn107304","volume":"77","author":"M Haag-Weber","year":"2012","unstructured":"Haag-Weber M, Eckardt KU, H\u00f6rl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-\u03b1 (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77(1):8\u201317. https:\/\/doi.org\/10.5414\/cn107304 (PMID: 22185963).","journal-title":"Clin Nephrol"},{"issue":"6","key":"533_CR41","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s11095-011-0621-4","volume":"29","author":"A Seidl","year":"2012","unstructured":"Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454\u201367. https:\/\/doi.org\/10.1007\/s11095-011-0621-4.","journal-title":"Pharm Res"},{"issue":"5","key":"533_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.xkme.2019.06.009","volume":"1","author":"JB Wish","year":"2019","unstructured":"Wish JB, Rocha MG, Martin NE, et al. Long-term safety of epoetin alfa-epbx for the treatment of anemia in ESKD: pooled analyses of randomized and open-label studies. Kidney Med. 2019;1(5):271\u201380. https:\/\/doi.org\/10.1016\/j.xkme.2019.06.009 (PMID: 32734207; PMCID: PMC7380401).","journal-title":"Kidney Med"},{"key":"533_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40261-018-0637-1","volume":"38","author":"D Goldsmith","year":"2018","unstructured":"Goldsmith D, Dellanna F, Schiestl M, Krendyukov A, Combe C. Epoetin biosimilars in the treatment of renal anemia: what have we learned from a decade of european experience? Clin Drug Investig. 2018;38:481\u201390. https:\/\/doi.org\/10.1007\/s40261-018-0637-1.","journal-title":"Clin Drug Investig"},{"key":"533_CR44","doi-asserted-by":"publisher","unstructured":"Yang J, Yu S, Yang Z et al. Efficacy and safety of supportive care biosimilars among cancer patients: a systematic review and meta-analysis. BioDrug. 2019; 33(4):373\u2013389. https:\/\/doi.org\/10.1007\/s40259-019-00356-3. https:\/\/www.researchgate.net\/publication\/333581066_Efficacy_and_Safety_of_SupportiveCare_Biosimilars_Among_Cancer_Patients_A_Systematic_Review_and_Meta-Analysis","DOI":"10.1007\/s40259-019-00356-3"},{"issue":"6","key":"533_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/03007995.2020.1754182","volume":"36","author":"T Shingaki","year":"2020","unstructured":"Shingaki T, Taki K, Koyanagi M, et al. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study. Curr Med Res Opin. 2020;36(6):947\u201358. https:\/\/doi.org\/10.1080\/03007995.2020.1754182 (Epub 2020 Apr 23 PMID: 32271092).","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"533_CR46","doi-asserted-by":"publisher","first-page":"e0195012","DOI":"10.1371\/journal.pone.0195012","volume":"13","author":"C Tieu","year":"2018","unstructured":"Tieu C, Lucas EJ, DePaola M, Rosman L, Caleb AG. Efficacy and safety of biosimilar insulins compared to their reference products: a systematic review. PLoS\u00a0One. 2018;13(4):e0195012. https:\/\/doi.org\/10.1371\/journal.pone.0195012 (Published 2018 Apr 18).","journal-title":"PLoS\u00a0One"},{"key":"533_CR47","unstructured":"EMA. Medicines, https:\/\/www.ema.europa.eu\/en\/medicines. Accessed 11 Nov 2021"},{"issue":"4","key":"533_CR48","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-020-00433-y","volume":"34","author":"HP Cohen","year":"2020","unstructured":"Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020;34(4):407\u201314. https:\/\/doi.org\/10.1007\/s40259-020-00433-y.","journal-title":"BioDrugs"},{"issue":"6","key":"533_CR49","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40261-020-00907-5","volume":"40","author":"TH Kim","year":"2020","unstructured":"Kim TH, Lee SS, Park W, et al. A 5-year retrospective analysis of drug survival, safety, and effectiveness of the infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Drug Investig. 2020;40(6):541\u201353. https:\/\/doi.org\/10.1007\/s40261-020-00907-5 (PMID: 32328979).","journal-title":"Clin Drug Investig"},{"issue":"4","key":"533_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40259-020-00421-2.PMID:32356239;PMCID:PMC7223987","volume":"34","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-marketing pooled safety analysis for CT-P13 treatment of patients with immune-mediated inflammatory diseases in observational cohort studies. BioDrugs. 2020;34(4):513\u201328. https:\/\/doi.org\/10.1007\/s40259-020-00421-2.PMID:32356239;PMCID:PMC7223987.","journal-title":"BioDrugs"},{"key":"533_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40259-019-00403-z","volume":"34","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Radominski SC, Kameda H, et al. Long-term efficacy, safety, and immunogenicity of the infliximab (IFX) biosimilar, PF-06438179\/GP1111, in patients with rheumatoid arthritis after switching from reference IFX or continuing biosimilar therapy: week 54\u201378 data from a randomized, double-blind, phase III trial. BioDrugs. 2020;34:197\u2013207. https:\/\/doi.org\/10.1007\/s40259-019-00403-z.","journal-title":"BioDrugs"},{"key":"533_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820982802","author":"S Fischer","year":"2021","unstructured":"Fischer S, Cohnen S, Klenske E, et al. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol. 2021. https:\/\/doi.org\/10.1177\/1756284820982802 (Published online January 14).","journal-title":"Therap Adv Gastroenterol"},{"key":"533_CR53","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-019-00355-4","volume":"33","author":"S Bellinvia","year":"2019","unstructured":"Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33:241\u201353. https:\/\/doi.org\/10.1007\/s40259-019-00355-4.","journal-title":"BioDrugs"},{"key":"533_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13075-019-1910-2","volume":"21","author":"HM Park","year":"2019","unstructured":"Park HM, Kim J, Park S-H, et al. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21:122. https:\/\/doi.org\/10.1186\/s13075-019-1910-2.","journal-title":"Arthritis Res Ther"},{"key":"533_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40744-019-00169-4","volume":"6","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-world evidence on etanercept biosimilar SB4 in etanercept-na\u00efve or switching patients: a systematic review. Rheumatol Ther. 2019;6:317\u201338. https:\/\/doi.org\/10.1007\/s40744-019-00169-4.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"533_CR56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/0929867323666161014153346","volume":"26","author":"L Martelli","year":"2019","unstructured":"Martelli L, Peyrin-Biroulet L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: a systematic review. Curr Med Chem. 2019;26(2):270\u20139. https:\/\/doi.org\/10.2174\/0929867323666161014153346 (PMID: 27758715).","journal-title":"Curr Med Chem"},{"key":"533_CR57","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s12325-018-0742-9","volume":"35","author":"S Numan","year":"2018","unstructured":"Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35:1295\u2013332. https:\/\/doi.org\/10.1007\/s12325-018-0742-9.","journal-title":"Adv Ther"},{"issue":"2","key":"533_CR58","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509\u201319. https:\/\/doi.org\/10.1111\/bjd.16102 (Epub 2018 Jan 9 PMID: 29094341).","journal-title":"Br J Dermatol"},{"issue":"44","key":"533_CR59","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.2174\/1381612824666171204095342","volume":"23","author":"P Avila-Ribeiro","year":"2017","unstructured":"Avila-Ribeiro P, Fiorino G, Danese S. The experience with biosimilars of infliximab in inflammatory bowel disease. Curr Pharm Des. 2017;23(44):6759\u201369. https:\/\/doi.org\/10.2174\/1381612824666171204095342 (PMID: 29205114).","journal-title":"Curr Pharm Des"},{"issue":"1","key":"533_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40259-016-0206-1","volume":"31","author":"M Radin","year":"2017","unstructured":"Radin M, Sciascia S, Roccatello D, Cuadrado MJ. Infliximab biosimilars in the treatment of inflammatory bowel diseases: a systematic review. BioDrugs. 2017;31(1):37\u201349. https:\/\/doi.org\/10.1007\/s40259-016-0206-1 (PMID: 28035633).","journal-title":"BioDrugs"},{"key":"533_CR61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-017-0658-4","volume":"19","author":"R Moots","year":"2017","unstructured":"Moots R, Azevedo V, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19:37. https:\/\/doi.org\/10.1007\/s11926-017-0658-4.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"533_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.7399\/fh.11280","volume":"44","author":"M\u00c1 Calleja-Hern\u00e1ndez","year":"2020","unstructured":"Calleja-Hern\u00e1ndez M\u00c1, Mart\u00ednez-Sesmero JM, Santiago-Josefat B. Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities. Farm Hosp. 2020;44(3):100\u20138. https:\/\/doi.org\/10.7399\/fh.11280 (PMID: 32452309).","journal-title":"Farm Hosp"},{"key":"533_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","volume":"8","author":"TWJ Huizinga","year":"2021","unstructured":"Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021;8:41\u201361. https:\/\/doi.org\/10.1007\/s40744-020-00259-8.","journal-title":"Rheumatol Ther"},{"key":"533_CR64","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","volume":"124","author":"M Weise","year":"2014","unstructured":"Weise M, Kurki P, Wolff-Holz E, Bielsky M-C, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191\u20136.","journal-title":"Blood"},{"issue":"21","key":"533_CR65","first-page":"1","volume":"8","author":"E Doevendans","year":"2019","unstructured":"Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies. 2019;8(21):1\u201310.","journal-title":"Antibodies"},{"key":"533_CR66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40259-019-00358-1","volume":"33","author":"J Yang","year":"2019","unstructured":"Yang J, Yu S, Yang Z, et al. Efficacy and safety of anti-cancer biosimilars compared to reference biologics in oncology: a systematic review and meta-analysis of randomized controlled trials. BioDrugs. 2019;33:357\u201371. https:\/\/doi.org\/10.1007\/s40259-019-00358-1.","journal-title":"BioDrugs"},{"issue":"1","key":"533_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/acr.23771","volume":"71","author":"HP Tony","year":"2019","unstructured":"Tony HP, Kr\u00fcger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88\u201394. https:\/\/doi.org\/10.1002\/acr.23771 (PMID: 30295429).","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"533_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40259-018-00331-4","volume":"33","author":"CH Suh","year":"2019","unstructured":"Suh CH, Yoo DH, Berrocal KA, et al. Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs. 2019;33:79\u201391. https:\/\/doi.org\/10.1007\/s40259-018-00331-4.","journal-title":"BioDrugs"},{"key":"533_CR69","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/rheumatology\/kez152","volume":"58","author":"SC Shim","year":"2019","unstructured":"Shim SC, Bo\u017ei\u0107-Majstorovi\u0107 L, Berrocal Kasay A, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology. 2019;58:2193\u2013202. https:\/\/doi.org\/10.1093\/rheumatology\/kez152.","journal-title":"Rheumatology"},{"key":"533_CR70","doi-asserted-by":"publisher","unstructured":"Esteva FJ, Lee S, Yu S, Kim M, Kim N, Stebbing J. 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-P6-17-03. Accessed 8 Dec 2021.","DOI":"10.1158\/1538-7445.SABCS18-P6-17-03"},{"issue":"7","key":"533_CR71","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(17)30434-5","volume":"18","author":"J Stebbing","year":"2017","unstructured":"Stebbing J, Baranay Y, Baryash V, et al. 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC). European Society for Medical Oncology (ESMO) congress 2019. Annals of Oncology Vol 30, Supplement 5 v64, Breast Cancer, Early Stage, Abstract 190P.Medicines for Europe. Lancet Oncol. 2017;18(7):917\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(17)30434-5.","journal-title":"Lancet Oncol"},{"key":"533_CR72","doi-asserted-by":"crossref","unstructured":"Pivot X, Pegram MD, Cortes J, et al. Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. Presented at: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021. Poster P2-13-04.","DOI":"10.1158\/1538-7445.SABCS21-P2-13-04"},{"key":"533_CR73","unstructured":"Medicines for Europe. Biosimilar Medicines. The total clinical experience with biosimilar medicines https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2020\/12\/BIOS5.pdf. Accessed 12 Nov 2021."},{"key":"533_CR74","unstructured":"Biosimilars in the EU\u2014Information guide for healthcare professionals. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 12 Nov 2021."},{"issue":"11","key":"533_CR75","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/pds.5100","volume":"29","author":"CPV Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez CPV, Mu\u00f1oz CG. The controversy around technical standards for similar biotherapeutics: barriers to access and competition? Pharmacoepidemiol Drug Saf. 2020;29(11):1518\u201322. https:\/\/doi.org\/10.1002\/pds.5100 (Epub 2020 Sep 22 PMID: 32964695).","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"533_CR76","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40259-018-0287-0","volume":"32","author":"FX Frapaise","year":"2018","unstructured":"Frapaise FX. The end of phase 3 clinical trials in biosimilars development? BioDrugs. 2018;32(4):319\u201324. https:\/\/doi.org\/10.1007\/s40259-018-0287-0 (PMID: 29943088).","journal-title":"BioDrugs"},{"issue":"4","key":"533_CR77","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/clpt.2013.17","volume":"93","author":"M McCamish","year":"2013","unstructured":"McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther. 2013;93(4):315\u20137. https:\/\/doi.org\/10.1038\/clpt.2013.17 (Epub 2013 Jan 25. PMID: 23443756; PMCID: PMC3604642).","journal-title":"Clin Pharmacol Ther"},{"issue":"30","key":"533_CR78","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40259-016-0184-3","volume":"2016","author":"J Liu","year":"2016","unstructured":"Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;2016(30):321\u201338. https:\/\/doi.org\/10.1007\/s40259-016-0184-3.","journal-title":"BioDrugs"},{"issue":"3","key":"533_CR79","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/clpt.2011.343","volume":"91","author":"M McCamish","year":"2012","unstructured":"McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405\u201317. https:\/\/doi.org\/10.1038\/clpt.2011.343 (Epub 2012 Feb 8 PMID: 22318617).","journal-title":"Clin Pharmacol Ther"},{"key":"533_CR80","unstructured":"Christl L. FDA\u2019s Overview of the regulatory guidance for the development and approval of biosimilar products in the US. https:\/\/www.fda.gov\/files\/drugs\/published\/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf. Accessed 12 Nov 2021."},{"issue":"3","key":"533_CR81","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-020-00422-1.PMID:32266678;PMCID:PMC7211192","volume":"34","author":"M Schiestl","year":"2020","unstructured":"Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, Trieb M, Bias P, Mar\u00e9chal-Jamil J. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34(3):297\u2013306. https:\/\/doi.org\/10.1007\/s40259-020-00422-1.PMID:32266678;PMCID:PMC7211192.","journal-title":"BioDrugs"},{"key":"533_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.006","author":"MC Bielsky","year":"2020","unstructured":"Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.006 (Epub ahead of print. PMID: 32916269).","journal-title":"Drug Discov Today"},{"key":"533_CR83","unstructured":"MHRA. Guidance on the licensing of biosimilar products. 2019. https:\/\/www.gov.uk\/government\/publications\/guidance-on-the-licensing-of-biosimilar-products\/guidance-on-the-licensing-of-biosimilar-products. Accessed 8 Apr 2022."},{"key":"533_CR84","doi-asserted-by":"publisher","unstructured":"Webster CJ, George KL, Woollett GR. Comparability of biologics: global principles, evidentiary consistency and\u00a0unrealized reliance. BioDrugs 2021;35(4):379\u2013387. https:\/\/doi.org\/10.1007\/s40259-021-00488-5. Accessed 12 Nov 2021.","DOI":"10.1007\/s40259-021-00488-5"},{"key":"533_CR85","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nrd4129","volume":"12","author":"HG Eichler","year":"2013","unstructured":"Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, et al. The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013;12:907\u201316. https:\/\/doi.org\/10.1038\/nrd4129.","journal-title":"Nat Rev Drug Discov"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00533-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00533-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00533-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T02:05:24Z","timestamp":1653789924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00533-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00533-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"13 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ministry of Health and Welfare of the Republic of Korea has provided funds to the WHO for this project through a voluntary contribution for the period of 1 December 2020\u201330 September 2022.\u00a0The open access of this article is also supported by the Norwegian Agency for Development Co-operation (Award number 73182 - 11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PK and H-NK planned the review. PK reviewed the materials and prepared a draft manuscript. H-NK designed and coordinated the work. NE, IK, MW, and EW-H provided technical comments to finalize the manuscript. The co-authors are listed in alphabetical order in the author section after the two primary authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}}]}}